A PHASE III, MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELAFIBRANOR IN ADULT PARTICIPANTS WITH PRIMARY SCLEROSING CHOLANGITIS
- Registry ID
- CLIN-60190-475
- Source registry
- HEALTH_CANADA
- Status
- Pending
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- IPSEN BIOSCIENCE INC
- Last update
- 2026-05-25
Conditions
- PRIMARY BILIARY CHOLANGITIS (PBC)
Related clinical trials
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, STUDY TO EVALUATE THE EFFECT OF SELADELPAR ON CLINICAL OUTCOMES IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (PBC) AND COMPENSATED CIRRHOSIS
- A PHASE III RANDOMISED, PARALLEL-GROUP, DOUBLE-BLIND, PLACEBO-CONTROLLED, TWO-ARM STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELAFIBRANOR 80 MG ON LONG-TERM CLINICAL OUTCOMES IN ADULT PARTICIPANTS WITH PRIMARY BILIARY CHOLANGITIS (PBC)
- A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTICENTER 12-WEEK STUDY WITH A 52-WEEK EXTENSION TO EVALUATE THE EFFICACY AND SAFETY OF TWO DOSES OF K-808 (PEMAFIBRATE) IN SUBJECTS WITH PRIMARY BILIARY CHOLANGITIS WITH INADEQUATE RESPONSE TO URSODEOXYCHOLIC ACID.
- A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF VOLIXIBAT IN THE TREATMENT OF CHOLESTATIC PRURITUS IN PATIENTS WITH PRIMARY BILIARY CHOLANGITIS (VANTAGE)
- ASSURE: AN OPEN LABEL LONG-TERM STUDY TO EVALUATE THE SAFETY AND TOLERABILITY OF SELADELPAR IN SUBJECTS WITH PRIMARY BILIARY CHOLANGITIS (PBC)
View on source registry